Clinical Trial Search

Primary: Percentage of Participants With Adverse Events (AEs), Serious AEs (SAEs), Related AEs, Discontinuation Due to AEs, or Death — 78.4; 5.9; 15.2; 7.8 percentage of…

Primary: Pain Relief Measured by the Brief Pain Inventory at 2 Months After Treatment — 28.0; 32.0 percentage of participants — p=0.03

Primary: Change From Baseline to Week 48/Termination Visit in the Total Unified Multiple System Atrophy Rating Scale (UMSARS Part I and II) — 7.2; 7.8 units on a scale — p=0.6984

Primary: Percentage of Patients Requiring Surgical Debridement for a Persistent Abscess Within 30 Days Following Initial Drainage — 3; 7 participants

Primary: Head Wrap Feasibility — 100 percentage of respondents

Primary: Comparison of the Change in IDS Symptom Scores Among Groups — 31.85; 30.92; 28.85; 14.08 units on IDS scale — p=0.07

Primary: Comparison of Diagnostic Ability of the Intervention Group's Ultrasound Exam to the Control Group's Physical Exam — 6.4; 7.6; 79.6; 79.3 units on a scale — p=0.11

Primary: Time to Sedation Score of 3-4 — 3.7; 2.8 minutes

Primary: Percentage of Participants With Disease Progression or Death (Data Cutoff 14 November 2011) — 92.3; 78.8 percentage of participants

Primary: Symptomatic Recurrent VTE, i.e., the Composite of DVT, Non-fatal PE, and Fatal PE — 130; 146 number or participants with an event — p=<0.0001

Primary: Patient Benefit Rate at 12 Weeks — 30.0; 34.2; 41.9 percentage of participants

Primary: Linagliptin: AUC 0-72 (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to 72 Hours) — 293; 288 nmol*h/L — p=<0.0001

Primary: Absence of Gastrointestinal (GI) Leak — 72; 81; 38 participants

Primary: Adjudicated Incidence of VTE — 29.0; 20.3; 15.7; 11.5 percentage of participants with VTE — p=0.003

Primary: Ventilation (Aim 1) — 1.19; 1.14; 1.35; 1.16 fraction of baseline — p=0.001